Zilucoplan ( DrugBank: Zilucoplan )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
11重症筋無力症10
62発作性夜間ヘモグロビン尿症3

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04297683
(ClinicalTrials.gov)
July 14, 20203/3/2020HEALEY ALS Platform Trial - Master ProtocolHEALEY ALS Platform TrialAmyotrophic Lateral SclerosisDrug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 TrehaloseMerit E. Cudkowicz, MDMassachusetts General HospitalRecruiting18 YearsN/AAll800Phase 2/Phase 3United States

11. 重症筋無力症


臨床試験数 : 332 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05514873
(ClinicalTrials.gov)
October 31, 202222/8/2022An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 InhibitorsA Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous ZilucoplanGeneralized Myasthenia GravisDrug: zilucoplan (RA101495)UCB Biopharma SRLNULLRecruiting18 Years85 YearsAll20Phase 3United States
2EUCTR2019-001565-33-PL
(EUCTR)
07/07/202119/04/2021Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc. (now part of UCB)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3France;United States;Canada;Spain;Poland;Norway;Germany;United Kingdom;Italy;Japan
3EUCTR2019-001565-33-ES
(EUCTR)
13/05/202014/01/2020Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3United States;France;Canada;Spain;Norway;Germany;United Kingdom;Japan;Italy
4EUCTR2019-001564-30-ES
(EUCTR)
13/05/202011/11/2019A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia GravisA Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
130Phase 3United Kingdom;Japan;Italy;United States;France;Canada;Spain;Norway;Germany
5EUCTR2019-001564-30-DE
(EUCTR)
31/03/202001/10/2019A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia GravisA Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
156Phase 3France;United States;Canada;Spain;Poland;Norway;Germany;United Kingdom;Italy;Japan;Korea, Republic of
6EUCTR2019-001565-33-IT
(EUCTR)
10/01/202007/01/2021Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
Product Code: [na]
INN or Proposed INN: zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3France;United States;Canada;Spain;Norway;Germany;United Kingdom;Japan;Italy
7EUCTR2019-001564-30-IT
(EUCTR)
10/01/202007/01/2021A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia GravisA Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
Product Code: [na]
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
130Phase 3France;United States;Canada;Spain;Norway;Germany;United Kingdom;Japan;Italy
8NCT04225871
(ClinicalTrials.gov)
December 23, 20192/10/2019Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia GravisGeneralized Myasthenia GravisDrug: zilucoplan (RA101495)Ra Pharmaceuticals, Inc.NULLActive, not recruiting18 YearsN/AAll200Phase 3United States;Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom
9EUCTR2019-001565-33-GB
(EUCTR)
30/10/201901/11/2019Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 3France;United States;Canada;Spain;Norway;Germany;Japan;Italy;United Kingdom
10EUCTR2019-001564-30-GB
(EUCTR)
29/10/201901/11/2019A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia GravisA Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE Generalized Myasthenia Gravis
MedDRA version: 20.0;Level: LLT;Classification code 10028415;Term: Myasthenia;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Zilucoplan
INN or Proposed INN: Zilucoplan
Ra Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
130Phase 3France;United States;Canada;Spain;Norway;Germany;Japan;Italy;United Kingdom

62. 発作性夜間ヘモグロビン尿症


臨床試験数 : 292 薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-003956-19-FI
(EUCTR)
13/02/201928/01/2019Study of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria - Phase 3 Study in Treatment-Naive Paroxysmal Nocturnal Hemoglobinuria Patients Paroxysmal Nocturnal Hemoglobinuria (PNH)
MedDRA version: 20.1;Level: LLT;Classification code 10055629;Term: Paroxysmal nocturnal hemoglobinuria;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Zilucoplan
Product Code: RA101495
INN or Proposed INN: ZILUCOPLAN
Other descriptive name: Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker
Ra Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
40Phase 3United States;Hong Kong;Taiwan;Finland;Spain;Turkey;Russian Federation;Italy;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Malaysia;Belgium;Brazil;Australia;Georgia;Germany;New Zealand;Korea, Republic of
2NCT03225287
(ClinicalTrials.gov)
July 17, 201717/7/2017Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical StudyA Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical StudyParoxysmal Nocturnal Hemoglobinuria (PNH)Drug: Zilucoplan (RA101495)Ra Pharmaceuticals, Inc.NULLTerminated18 YearsN/AAll19Phase 2United States;Australia;Canada;Finland;Germany;Hungary;New Zealand;United Kingdom;Denmark
3EUCTR2016-003523-34-FI
(EUCTR)
06/04/201727/12/2016Extension Study of RA101495 in Paroxysmal Nocturnal Hemoglobinuria (PNH)A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study Paroxysmal Nocturnal Hemoglobinuria (PNH)
MedDRA version: 21.1;Level: LLT;Classification code 10055629;Term: Paroxysmal nocturnal hemoglobinuria;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Zilucoplan
Product Code: RA101495
INN or Proposed INN: Zilucoplan
Other descriptive name: Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker
Ra Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
28Phase 2United States;Hungary;Finland;Denmark;Australia;Germany;United Kingdom;New Zealand